Smaller appetites, new opportunities

GLP-1 drugs are changing more than waistlines: they could reshape spending on food, dining and beauty. Poles spent nearly PLN 3.4 billion on these medicines in 2025.

Leki na odchudzanie przestają być wyłącznie tematem rynku farmaceutycznego. Zmieniają apetyt, nawyki zakupowe i oczekiwania konsumentów. Producenci żywności, restauratorzy i firmy kosmetyczne zaczynają dostrzegać konsekwencje popularności terapii GLP-1/fot. gettyimages
Weight-loss drugs are no longer just a topic for the pharmaceutical market. They are changing consumers’ appetites, shopping habits, and expectations. Food manufacturers, restaurant owners, and cosmetics companies are beginning to recognize the implications of the popularity of GLP-1 therapies. Photo: Getty Images
Loading the Elevenlabs Text to Speech AudioNative Player...

Poles have already spent PLN 3.4 billion on GLP-1 drugs. But their popularity could bring changes far beyond weight loss. How will the slimming trend affect food producers, restaurants and the beauty market?

Drugs that support weight loss are beginning to change not only consumers’ eating habits, but also their spending. According to a Bain & Company analysis based on US payment card transaction data, people using GLP-1 drugs spend an average of 3–4% less on groceries and around 5% less on fast food.

The composition of grocery purchases is changing too. GLP-1 users report spending less on sweets, salty snacks, bread and carbonated drinks, among other products. At the same time, interest in fresh fruit and vegetables, protein products and supplements is growing. Restaurants are also feeling the effects. Among GLP-1 users in the UK, spending on burgers is 8% lower. In Germany, spending on pizza and Italian food is down 8%. Spending on salads, meanwhile, is rising — by 5% in Germany, for example. What does the situation look like in Poland?

GLP-1 and consumer goods

According to analytics firm PEX, Poles spent nearly PLN 3.4 billion in 2025 on GLP-1 drugs for diabetes and weight loss.

But as Anna Radowicka, a dietitian and food technologist, points out, the growing popularity of therapies based on GLP-1 receptor agonists could have consequences beyond the pharmaceutical market.

“These drugs affect feelings of hunger and fullness and, as a result, can reduce energy intake. That raises questions not only about how much food people buy, but also about changes in the composition of their shopping baskets and their expectations of products. From the food market’s perspective, there may be a growing group of consumers who eat less. As a result, what goes into a smaller portion becomes more important. So it is not necessarily just about ‘less food’ and a shift toward smaller portions. It is also about foods with high nutritional density,” Radowicka says.

In her view, when appetite is significantly reduced, adequate intake of protein, fiber, vitamins and minerals, as well as the overall quality of the diet, becomes especially important.

“During weight loss, it is also important to limit the loss of lean body mass. That is why adequate protein intake and physical activity, including resistance training adapted to the patient’s abilities, are important elements of care. But that does not mean everyone using GLP-1 drugs needs special ‘food for Ozempic or Wegovy users,’” the dietitian says.

From a nutritional perspective, a separate food category is not needed for treatment to be effective. The foundation remains a properly balanced diet tailored to the patient’s health, energy intake, food tolerance and individual needs. Medication does not replace nutrition, physical activity or medical care.

“From a business perspective, however, an interesting niche is emerging. Nestlé has introduced the Vital Pursuit brand in the US, positioning it in part for people using GLP-1 drugs. The approach includes smaller portions and products that emphasize protein, fiber and nutritional value. This shows that the industry is already watching this group of consumers. The market may therefore develop less toward another wave of products with ‘protein’ written in large letters and more toward products that meet the need: ‘I am eating less, so what I eat should provide enough of the key nutrients.’ That could mean smaller portions, appropriate amounts of protein and fiber, high nutritional density and convenient formats,” Radowicka adds.

She believes the phenomenon is also worth watching in the restaurant industry. People using these therapies may be interested in smaller portions or more flexibility in how their meals are put together.

According to Reuters, Heineken, the world’s second-largest brewer after AB InBev, has told its hospitality customers that GLP-1 drugs such as Ozempic could reduce the desire to drink alcohol. The company also warned English pubs that maintaining the traditional model of socializing over several pints of beer could become more difficult.

Expert's perspective

A shift from quantity to quality

GLP-1 drugs affect feelings of hunger and fullness, as well as the brain’s reward system. As a result, some patients eat less, have less desire for sweets and highly processed foods, and are less likely to eat impulsively. That could put greater pressure on categories driven by spontaneous purchases.
At the same time, when people eat less food, its quality becomes more important. After all, the goal of treatment is not simply to lose weight. It is important to reduce body fat while protecting muscle mass, physical fitness and metabolic health. Protein, fiber, vegetables, whole grains, groats, seeds, legumes and adequate hydration therefore become particularly important.
This, in turn, creates an opportunity for the fast-moving consumer goods sector. Products that are high in protein, rich in fiber and nutritionally well balanced may gain importance. The product format itself may also change. A smaller portion with better ingredients and greater nutritional value could become more attractive than the traditional “more for the same price” model.
A similar change could affect restaurants. People taking GLP-1 drugs will still want to meet friends and go out to eat, because food also has a social dimension. What is more, in clinical practice we see that some people living with obesity become more willing to return to social life as their health and well-being improve.
What may change is what customers expect from a restaurant. A smaller, well-balanced portion, a good source of protein, high-quality ingredients and the ability to adjust the size of a dish may become more important.
From the perspective of lifestyle medicine, this may therefore mean less a decline in consumption than a shift in emphasis from quantity to quality. We may be entering a period in which consumers eat less. What they choose, the quality of the product and its nutritional value will matter more.

GLP-1 and food producers

“Everything I hear suggests that the use of these drugs is already affecting the food market. But it is too early to try to estimate or measure the scale of the phenomenon in Poland. We have to assume that we are dealing with a strong trend: access to new drugs that help reduce body weight and, consequently, suppress appetite. Although they are used to treat diabetes, their effect on weight loss has also proved significant for other reasons. It seems to me that their effect is socially desirable. That is why we treat this as a potentially major trend that needs to be taken into account. But that does not mean we will stop eating and drinking and consume only water and sprouts tomorrow,” says Krzysztof Pawiński, CEO of Maspex Group.

In his view, food must also provide pleasure.

“Meeting hunger and thirst are needs that are too basic to be the end of our expectations of food. Everything I have learned in 36 years working in the food industry tells me that food must meet three basic human needs: health, pleasure and convenience,” Pawiński says.

Will food producers offer a special category of products in the future for people who want to eat less?

“That is already happening, because the biggest trend today is functional food. Almost every product now carries an additional promise beyond its basic function of satisfying hunger or thirst. For example, it might supplement the diet with protein, fiber or vitamin complexes. Jokingly, I would say cigarettes are probably the only thing that does not contain added vitamins anymore. The expectation that food will have additional health benefits is very strong and visible across the market’s broad offering. That does not mean, however, that consumer needs are fixed. We are dealing with a wave. Expectations change, and products begin to offer new benefits along with them,” the Maspex CEO adds.

He points out that just three years ago, consumers were looking for different things. Vitamins and minerals played a bigger role. Today, even in beverages, functions that might once have seemed basic — such as hydration — are gaining importance.

“How a product is positioned and how its additional properties are emphasized are enormously important in every food category. Today, the message ‘differentiate or die’ is clearer than ever. I believe we will see new consumer expectations in the future. That is a natural evolution connected with changes in our lifestyles; nothing happens overnight. Who knows whether we might one day see specialized weight-management functions available in ordinary food products too? We are already seeing weight-loss drugs in tablet form. This is the first year that GLP-1 is also available in that form,” Pawiński adds.

Ozempic and the beauty industry

According to Agnieszka Lew-Mirska, a certified aesthetic medicine physician, internal medicine specialist and founder of Self Esteem Clinic, the growing popularity of GLP-1 analogues will also have a very clear impact on the beauty and aesthetic medicine industries.

“I can already see it in my practice. I am increasingly seeing patients who are very happy with their weight loss. At the same time, however, they notice a loss of facial volume, with more pronounced lines and changes to their facial contours, as well as increased skin laxity across the body. Some say their figure looks better, but their face has begun to look more tired or older, and their skin is starting to ‘sag.’ This is not an effect specific to one drug, although the term ‘Ozempic face’ is used publicly. Similar changes can occur with any substantial weight loss, particularly when it is rapid. Facial fat provides support, so losing it can lead to changes in facial contours, tissue firmness and skin condition,” the physician explains.

This is also changing the approach to aesthetic medicine. It is not simply a matter of replacing lost volume with large amounts of filler. Solutions that improve skin quality, density and firmness while providing a lifting effect without surgery are gaining importance.

“Laser technologies and other high-tech solutions are becoming increasingly important. These include linear ultrasound, tissue biostimulators that encourage skin remodeling and collagen production, as well as autologous fillers and treatments that use the patient’s own biological material. They make it possible to combine a very natural result with work on tissue quality. At the same time, this issue cannot be viewed solely through the lens of procedures. As an aesthetic medicine physician, I work closely with a lifestyle medicine physician and a dietitian, because the way a patient loses weight matters too. An appropriate pace of weight loss, protein intake, properly selected supplements, hydration, physical activity and protection of muscle mass also matter for skin condition,” the expert says.

That is why, in her view, taking a proactive approach is becoming increasingly important for patients using GLP-1 drugs.

“If we know someone is beginning a substantial weight-loss process, we can support skin quality and density at the same time, rather than reacting only when changes are already very visible. For the beauty industry, this means not only growing interest in particular procedures, but above all a change in thinking: from a single aesthetic correction toward long-term patient care and maintaining good tissue quality throughout the weight-loss process,” Lew-Mirska says.

Key Takeaways

  1. The effects could extend beyond pharmaceuticals. The growing popularity of therapies based on GLP-1 receptor agonists may have consequences for other industries.
  2. GLP-1 could change the consumer goods market. People using these drugs may buy fewer sweets, snacks and highly processed products, while choosing more foods rich in protein, fiber and other nutrients.
  3. The beauty industry could benefit. Rapid weight loss is associated in some patients with a loss of facial volume and skin laxity, increasing the importance of treatments that support skin density, firmness and quality.